AR047682A1 - Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina - Google Patents

Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina

Info

Publication number
AR047682A1
AR047682A1 ARP050100564A ARP050100564A AR047682A1 AR 047682 A1 AR047682 A1 AR 047682A1 AR P050100564 A ARP050100564 A AR P050100564A AR P050100564 A ARP050100564 A AR P050100564A AR 047682 A1 AR047682 A1 AR 047682A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkenyl
independently
substituted
halogens
Prior art date
Application number
ARP050100564A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR047682A1 publication Critical patent/AR047682A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Productos intermedios para la preparacion de dichos compuestos; composiciones farmacéuticas que comprenden dichos compuestos y al uso de dichos compuestos en un procedimiento para tratar ciertos trastornos del sistema nervioso central (SNC) u otros. Reivindicacion 1: Un compuesto de la formula (1), o una sal, solvato o profármaco del mismo farmacéuticamente aceptable; donde Q es N o CH; donde R1, R2 y R3 son cada uno de forma independiente hidrogeno, halogeno, alquilo C1-9, alquenilo C2- 9, alquinilo C2-9, cicloalquilo C3-8, -O-alquilo C1-9, -O-alquenilo C2-9, alquil C1-8-O-alquilo C1-6, C:::N,-NO2, -COOR4, -CONR4R5, -NR4R5, -COR5 o -COOH, donde dichos alquilo, alquenilo y alquinilo están opcionalmente sustituidos con de 1 a 3 halogenos; donde R4 y R5 son de forma independiente H, alquilo C1-6 o alquenilo C2-8, donde dichos alquilo y alquenilo están opcionalmente sustituidos con de 1 a 3 átomos de halogeno; y, cuando R1, R2 y R3 son de forma independiente -O-alquilo, -O- alquenilo, o alquilo, alquenilo o alquinilo, R2 y R1, o R1 y R3, pueden estar opcionalmente conectados para formar un anillo de 5 a 6 miembros; R6 y R7 son de forma independiente hidrogeno; -C(=O)-X; -S(=O)2-X, -N(Y)-S(=O)2-X o -N(Y)-C(=O)-X, donde X es un grupo alquilo C1-6 insustituido o sustituido con uno o más halogenos, O-alquilo C1-6 insustituido o sustituido con uno o más halogenos, un grupo arilo C6-14 insustituido o sustituido con uno o dos sustituyentes, un grupo -NR8R9 o una formula (2), donde dichos sustituyentes del grupo arilo C6-14 se seleccionan de forma independiente de alquilo C1-6, -O-alquilo C1-6, halogeno, -C:::N, -NO2, -COOR4, -CONR4R5, -NR4R5, -COR4 y -COOH, y alquilo C1-6 sustituido con de 1 a 3 halogenos; Y es hidrogeno o alquilo C1-6; n es 0 o 1; R8 y R9 son cada uno de forma independiente alquilo C1-6 o hidrogeno; Z es oxígeno o NR10, donde R10 es hidrogeno o alquilo C1-6; donde R11 y R12 son de forma independiente H, halogeno, C:::N, -COOH, -COOR4, - CONR4R5, COR4, -NR4R5, -OH, arilo C6-14, heteroarilo de 5 a 12 miembros, alquilo C1-6, alquenilo C2-6, alquinilo C2-6 o cicloalquilo C3-8, donde dichos alquilo, alquenilo y alquinilo están opcionalmente sustituidos de forma independiente con de 1 a 3 halogenos.
ARP050100564A 2004-02-18 2005-02-17 Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina AR047682A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54556504P 2004-02-18 2004-02-18

Publications (1)

Publication Number Publication Date
AR047682A1 true AR047682A1 (es) 2006-02-01

Family

ID=34910729

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100564A AR047682A1 (es) 2004-02-18 2005-02-17 Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina

Country Status (14)

Country Link
US (1) US7268142B2 (es)
EP (1) EP1723134A2 (es)
JP (1) JP2007523152A (es)
AR (1) AR047682A1 (es)
BR (1) BRPI0507839A (es)
CA (1) CA2556413A1 (es)
DO (1) DOP2005000022A (es)
GT (1) GT200500027A (es)
NL (1) NL1028321C2 (es)
PA (1) PA8624101A1 (es)
PE (1) PE20050694A1 (es)
TW (1) TW200528446A (es)
UY (1) UY28750A1 (es)
WO (1) WO2005082883A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101389246B1 (ko) 2004-07-15 2014-04-24 브리스톨-마이어스스퀴브컴파니 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
AU2006279548A1 (en) * 2005-08-16 2007-02-22 Amgen, Inc. Phosphodiesterase 10 inhibitors
JP2009527542A (ja) * 2006-02-23 2009-07-30 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害薬としての置換キナゾリン
US20070287707A1 (en) * 2006-02-28 2007-12-13 Arrington Mark P Phosphodiesterase 10 inhibitors
US20090099175A1 (en) * 2006-03-01 2009-04-16 Arrington Mark P Phosphodiesterase 10 inhibitors
US20070265258A1 (en) * 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
JP2009529060A (ja) * 2006-03-08 2009-08-13 アムゲン インコーポレイティッド ホスホジエステラーゼ１０阻害剤としてのキノリン及びイソキノリン誘導体
HRP20120835T1 (hr) * 2006-07-10 2012-11-30 H. Lundbeck A/S (3-aril-piperazin-1-il) derivati 6,7-dialkoksikinazolina, 6,7-dialkoksiftalazina i 6,7-dialkoksiizokinolina
US7786139B2 (en) 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
MX2009012474A (es) * 2007-05-18 2009-12-18 Wyeth Corp Compuestos de quinazolina.
US7858620B2 (en) 2007-09-19 2010-12-28 H. Lundbeck A/S Cyanoisoquinoline
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
UA102693C2 (ru) * 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
KR101830447B1 (ko) * 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
CN102638982B (zh) 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TW201200516A (en) 2009-12-17 2012-01-01 Lundbeck & Co As H Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
EP2539342B1 (en) 2010-02-26 2015-04-15 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine compounds and their use as pde10 inhibitors
TW201215607A (en) 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
TW201206935A (en) 2010-07-16 2012-02-16 Lundbeck & Co As H Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor
DE102010042833B4 (de) 2010-10-22 2018-11-08 Helmholtz-Zentrum Dresden - Rossendorf E.V. Neue Halogenalkoxychinazoline, deren Herstellung und Verwendung
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
KR20140009372A (ko) 2011-02-18 2014-01-22 알러간, 인코포레이티드 포스포다이에스테라제 10(pde10a)의 억제제로서의 치환된 6,7-다이알콕시-3-아이소퀴놀리놀 유도체
WO2013045607A1 (en) 2011-09-30 2013-04-04 H. Lundbeck A/S Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors
WO2013050527A1 (en) 2011-10-05 2013-04-11 H. Lundbeck A/S Quinazoline derivatives as pde10a enzyme inhibitors
TWI570124B (zh) 2011-12-21 2017-02-11 Ｈ 朗德貝克公司 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
EP2963037B1 (en) 2013-02-27 2019-03-27 Mochida Pharmaceutical Co., Ltd. Novel pyrazole derivative
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
JP2018502900A (ja) * 2014-10-22 2018-02-01 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ジスコイジンドメイン受容体１を標的化する小分子阻害剤およびその使用
JP7720847B2 (ja) * 2019-12-18 2025-08-08 シーエイチディーアイ ファウンデーション，インコーポレーテッド ハンチンチンタンパク質をイメージングするための化合物及びプローブ
MX2022015400A (es) * 2020-06-05 2023-03-16 Noema Pharma Ag Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del sindrome de tourette.
US12544364B2 (en) 2020-06-05 2026-02-10 Noema Pharma Ag Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome
CN114456184B (zh) * 2022-02-21 2023-08-22 南华大学附属第一医院 一种3-芳基异喹啉衍生物及其制备与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674791A (en) * 1968-03-26 1972-07-04 Marion Laboratories Inc Benzamido 2 lower alkyl decahydroisoquinolines
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4

Also Published As

Publication number Publication date
NL1028321C2 (nl) 2006-05-23
WO2005082883A3 (en) 2007-04-26
PE20050694A1 (es) 2005-10-04
US7268142B2 (en) 2007-09-11
TW200528446A (en) 2005-09-01
BRPI0507839A (pt) 2007-05-08
EP1723134A2 (en) 2006-11-22
CA2556413A1 (en) 2005-09-09
JP2007523152A (ja) 2007-08-16
DOP2005000022A (es) 2005-08-30
UY28750A1 (es) 2005-09-30
PA8624101A1 (es) 2005-11-25
NL1028321A1 (nl) 2005-08-19
WO2005082883A2 (en) 2005-09-09
US20050182079A1 (en) 2005-08-18
GT200500027A (es) 2005-10-24

Similar Documents

Publication Publication Date Title
AR047682A1 (es) Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR032467A1 (es) Derivados de piridina, procedimiento para prepararlos, el uso de dichos derivados para la preparacion de medicamentos y los medicamentos que contienen dichos derivados
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR049388A1 (es) Heterociclos como inhibidores de aldosterona sintasa
AR081649A1 (es) Compuestos heteroarilo nitrogenados
AR066562A1 (es) Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos
AR047966A1 (es) Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropico
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
AR063015A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer
AR003428A1 (es) Derivados de pirimidindiona o triazindiona como antagonista de los receptores adrenergenicos alfa1, procedimiento para su preparacion, composicion farmaceutica que los contiene y uso de dichos compuestos para la preparacion de medicamentos.
CO5700774A2 (es) Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1
AR058073A1 (es) Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
AR062731A1 (es) Derivados de quinazolinona e isoquinolinona, composiciones farmaceuticas que los contienen, y su uso para tratar o prevenir trastornos relacionados con el estres o la depresion.
AR082945A1 (es) Derivados de imidazo[1,2-b]piridazina como inhibidores de la trk
AR071300A1 (es) Compuestos; composiciones farmaceuticas en base al compuesto y uso del mismo para la manufactura de un medicamento
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
AR051092A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
AR051095A1 (es) Derivados heterociclicos y su uso comoinhibidores de la estearoil-coa desaturasa
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
AR064533A1 (es) Derivados de isoquinolina e isoquinolinona sustituidos y su uso en la produccion de un medicamento para el tratamiento de enfermedades relacionadas con la inhibicion de la rho-quinasa.
AR056980A1 (es) Derivados de dihidrobenzofurano, composiciones farmaceuticas, y uso de los mismos
AR040047A1 (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6
PE20081844A1 (es) DERIVADOS DE INDOL-3-IL-CARBONIL-AZASPIROPIPERIDINA COMO ANTAGONISTAS DEL RECEPTOR V1a

Legal Events

Date Code Title Description
FB Suspension of granting procedure